We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Decoding Improved for Neurodevelopmental Disorders

By LabMedica International staff writers
Posted on 23 Oct 2017
DLG2 gene study as a case in point that will help facilitate future diagnosis of children with neurodevelopmental disorders (NDDs), such as intellectual disability, autism, or early-onset symptoms of psychiatric diseases such as schizophrenia.

NDDs are a group of often severe pediatric conditions. More...
The recent development of higher resolution genetic diagnostic tools has underlined the prevalence of genetic anomalies (e.g. gene copy-number variations) in children with NDDs.

In the study, two patients at Queen Fabiola Children's University Hospital (HUDERF; Brussels, Belgium) with NDDs (here cognitive and behavioral symptoms) showed partial loss, by deletion, of the DLG2 gene, which plays an important role in the development, plasticity, and stability of synapses.

A research team led by Dr. Guillaume Smits, Dr. Nicolas Deconinck, and Dr. Catheline Vilain of HUDERF and Prof. Gianluca Bontempi of ULB collaborated through the Interuniversity Institute of Bioinformatics in Brussels (IB), a joint research institute at Free University of Brussels (ULB; Brussels, Belgium) and Vrije Universiteit Brussel (VUB). Together, they worked at integrating large genomic, epigenomic, transcriptomic, and clinical datasets. The computational experiments, performed by Claudio Reggiani, a PhD student, pinpointed 2 novel DLG2 promoters and coding exons conserved in human and mouse and present in the fetal brain. The deletion of these new regions was found statistically associated with developmental delay and intellectual disability in 2 independent patient cohorts, supporting the pathogenic role of these new elements into the neurodevelopmental symptoms of both HUDERF patients. The findings are presented in a paper and summarized in a video.

From a medical perspective, the findings will help medical doctors in improving future diagnosing of children with NDDs. From a scientific point of view, this work shows how the in silico integration of multiple large datasets can bring knowledge about the genome. It also provides elegant progress into the molecular cause of NDDs and improves fundamental knowledge about the DLG2 gene.

The study, by Reggiani C et al, was published July 19, 2017, in the journal Genome Medicine.

Related Links:
Queen Fabiola Children's University Hospital
Free University of Brussels
Vrije Universiteit Brussel

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.